Login to Your Account



No Relief for Genzyme as APB Failure Dents Renal Franchise

By Jennifer Boggs


Thursday, November 19, 2009
Genzyme Corp. is dropping further work on its advanced phosphate binder (APB) - the product expected to save the Cambridge, Mass.-based firm's renal franchise from the looming patent cliff - after it failed to show improvement over Renvela in a Phase II/III trial, leaving analysts and investors to wonder what's next for the big biotech, which has suffered more than its share of bad news in the past several months. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription